BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 8:53:00 PM | Browse: 461 | Download: 372
Publication Name World Journal of Gastroenterology
Manuscript ID 3449
Country of Manuscript Source China
2013-05-01 12:59
Peer-Review Started
2013-05-03 10:33
To Make the First Decision
2013-05-14 18:36
Return for Revision
2013-05-19 18:14
2013-06-05 06:06
Second Decision
2013-07-31 14:35
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-08-01 05:21
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-08-13 12:56
Typeset the Manuscript
2013-08-21 11:17
Publish the Manuscript Online
2013-09-09 09:30
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Infectious Diseases
Manuscript Type Case Report
Article Title Lactic acidosis during telbivudine treatment for HBV: A case report and literature review
Manuscript Source Invited Manuscript
All Author List Jia-Lin Jin, Piao Hu, Jia-Hong Lu, Su-Shan Luo, Xiao-Yun Huang, Xin-Hua Weng and Ji-Ming Zhang
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 81071354
National Natural Science Foundation of China 81271833
National “973’’ Project 2012CB519001
National Science and Technology Major Project of China 2012ZX10002007-001-002
National Science and Technology Major Project of China 2013ZX10002001
Corresponding author Ji-Ming Zhang, MD, Department of Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhonglu, Jing'an District, Shanghai 200040, China. jmzhang@fudan.edu.cn
Keywords Lactic acidosis/hyperlactatemia; Telbivudine; Hepatitis B virus; Nucleoside analogue; Adverse effects
Core Tip Myopathy is the most common side effect resulting from telbivudine. Lactic acidosis (LA) is rare but fatal, and LA caused by telbivudine has never been reported. Here, we report the first case of chronic hepatitis B developing severe refractory LA during telbivudine monotherapy. This case shows that telbivudine may cause muscle damage and even lead to fatal LA in chronic hepatitis B patients. Patients under telbivudine treatment should be closely monitored for muscular, blood lactate and other mitochondrial toxicity associated side effects.
Publish Date 2013-09-09 09:30
Citation Jin JL, Hu P, Lu JH, Luo SS, Huang XY, Weng XH, Zhang JM. Lactic acidosis during telbivudine treatment for HBV: A case report and literature review. World J Gastroenterol 2013; 19(33): 5575-5580
Url http://www.wjgnet.com/1007-9327/full/v19/i33/5575.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i33.5575
Full Article (PDF) WJG-19-5575.pdf
Manuscript File 3449-Review.doc
Answering Reviewers 3449-Answering reviewers.pdf
Copyright License Agreement 3449-Copyright assignment.pdf
Peer-review Report 3449-Peer review(s).pdf
Scientific Editor Work List 3449-Scientific editor work list.doc